Histologic factors predicting invasion in patients with ductal carcinoma in situ (DCIS) in the preoperative core biopsy

Nemer, Areej M. Al

doi:10.1016/j.prp.2017.02.016

Cited by 5 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis of studies published prior to 2011 did not find an increased risk of upstaging of DCIS to invasive cancer in the presence of comedo necrosis in pooled estimates from the 9 studies reporting this variable [12]. Since then, to our knowledge, out of five studies that have investigated the significance of comedo necrosis on CNB [13][14][15][16][17], only two have shown it to be an independent predictor of invasive cancer on excision [13,14].…”

Section: Discussionmentioning

confidence: 99%

Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ

et al. 2019

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ

et al. 2019

View full text Add to dashboard Cite

“…As previously mentioned, comedo necrosis is an adverse prognostic factor in DCIS [ 30 , 33 ]. However, its predictive value and its features such as ductal spread are still under debate in DCIS [ 34 , 35 ]. We noted that comedo necrosis and lobular cancerization are related to a higher peritumoral infiltration of mature DCs.…”

Section: Discussionmentioning

confidence: 99%

Dendritic Cell Subpopulations Are Associated with Morphological Features of Breast Ductal Carcinoma In Situ

Szpor,

Streb,

Glajcar

et al. 2023

IJMS

View full text Add to dashboard Cite

Ductal carcinoma in situ (DCIS) is the preinvasive form of breast cancer (BC). It is disputed whether all cases of DCIS require extensive treatment as the overall risk of progression to BC is estimated at 40%. Therefore, the crucial objective for researchers is to identify DCIS with significant risk of transformation into BC. Dendritic cells (DC) are professional antigen presenting cells and as such play a pivotal role in the formation of immune cells that infiltrate in breast tumors. The aim of this study was to investigate the relationship between the density of DCs with different superficial antigens (CD1a, CD123, DC-LAMP, DC-SIGN) and various histopathological characteristics of DCIS. Our evaluation indicated that CD123+ and DC-LAMP+ cells were strongly associated with maximal tumor size, grading and neoductgenesis. Together with CD1a+ cells, they were negatively correlated with hormonal receptors expression. Furthermore, the number of DC-LAMP+ cells was higher in DCIS with comedo necrosis, ductal spread, lobular cancerization as well as comedo-type tumors, while CD1a+ cells were abundant in cases with Paget disease. We concluded that different subpopulations of DCs relate to various characteristics of DCIS. Of the superficial DCs markers, DC-LAMP seems particularly promising as a target for further research in this area.

show abstract

“…Many studies have ascertained that upstaging is more frequent in high-grade DCIS than in low-and intermediate-grade DCIS. 55,[59][60][61][62] Nevertheless, a significant proportion of nonhigh-grade pure DCIS shows synchronous invasive carcinoma in the subsequent resection specimen. 57 Attempts have been made to identify additional histological and immunohistochemical features for prediction of concurrent invasive carcinoma.…”

Section: Risk Assessment For Synchronous Invasion At the Biopsy Levelmentioning

confidence: 99%

“…Overall, the prediction of synchronous invasive cancer when pure DCIS is diagnosed at the biopsy level remains challenging. Many studies have ascertained that upstaging is more frequent in high‐grade DCIS than in low‐ and intermediate‐grade DCIS . Nevertheless, a significant proportion of nonhigh‐grade pure DCIS shows synchronous invasive carcinoma in the subsequent resection specimen .…”

Section: Introductionmentioning

confidence: 99%

A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast

Bockstal

Agahozo

Koppert

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Ductal carcinoma in situ (DCIS) of the breast is a nonobligate precursor of invasive breast cancer, accounting for 20 % of screen‐detected breast cancers. Little is known about the natural progression of DCIS because most patients undergo surgery upon diagnosis. Many DCIS patients are likely being overtreated, as it is believed that only around 50 % of DCIS will progress to invasive carcinoma. Robust prognostic markers for progression to invasive carcinoma are lacking. In the past, studies have investigated women who developed a recurrence after breast‐conserving surgery (BCS) and compared them with those who did not. However, where there is no recurrence, the patient has probably been adequately treated. The present narrative review advocates a new research strategy, wherein only those patients with a recurrence are studied. Approximately half of the recurrences are invasive cancers, and half are DCIS. So‐called “recurrences” are probably most often the result of residual disease. The new approach allows us to ask: why did some residual DCIS evolve to invasive cancers and others not? This novel strategy compares the group of patients that developed in situ recurrence with the group of patients that developed invasive recurrence after BCS. The differences between these groups could then be used to develop a robust risk stratification tool. This tool should estimate the risk of synchronous and metachronous invasive carcinoma when DCIS is diagnosed in a biopsy. Identification of DCIS patients at low risk for developing invasive carcinoma will individualize future therapy and prevent overtreatment.

show abstract

Histologic factors predicting invasion in patients with ductal carcinoma in situ (DCIS) in the preoperative core biopsy

Cited by 5 publications

References 25 publications

Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ

Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ

Dendritic Cell Subpopulations Are Associated with Morphological Features of Breast Ductal Carcinoma In Situ

A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast

Contact Info

Product

Resources

About